Part 4: Interaction between unproven cellular therapies and global medicinal product approval regulatory frameworks

Cytotherapy. 2016 Jan;18(1):127-37. doi: 10.1016/j.jcyt.2015.11.003.

¹ NantKwest, Inc, Culver City, California, USA. ISCT Past Co-Chair, NA LRA Committee 2011-2014. Electronic address: [email protected].
² St Jude Children's Research Hospital, Memphis, Tennessee, USA. ISCT Past Co-Chair, NA LRA Committee 2011-2014. ISCT North America, Regional Vice-President 2014-2016.
³ Department of Pathology, University of Melbourne; Cell Therapies Pty Ltd, East Melbourne, Australia, ISCT Australia & New Zealand, Past Regional Vice President 2012-2014 and Chair, ISCT ANZ LRA Committee 2014-2016.
⁴ Andalusian Initiative for Advanced Therapies, Junta de Andalucía, Sevilla, Spain. Chair, ISCT EU LRA Committee 2014-2016.
⁵ Moffitt Cancer Center and Research Institute, Tampa, Florida, USA. Chair, ISCT NA LRA Committee 2014-2016. Co-Editor of the Telegraft.

No abstract available